Shares of Impax Laboratories Inc (NASDAQ:IPXL) have been given a consensus rating of “Hold” by the eighteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $19.41.
A number of research firms recently commented on IPXL. Cantor Fitzgerald set a $35.00 price target on shares of Impax Laboratories and gave the stock a “buy” rating in a report on Friday, December 15th. Cowen reaffirmed a “hold” rating and issued a $16.00 price target on shares of Impax Laboratories in a report on Friday, November 10th. Leerink Swann began coverage on shares of Impax Laboratories in a report on Tuesday, January 2nd. They issued an “outperform” rating and a $22.00 price target on the stock. UBS Group lifted their price target on shares of Impax Laboratories from $12.00 to $16.00 and gave the stock a “sell” rating in a report on Monday, October 30th. Finally, Zacks Investment Research raised shares of Impax Laboratories from a “strong sell” rating to a “hold” rating in a report on Monday, January 15th.
A number of hedge funds have recently modified their holdings of the business. Commerce Bank raised its holdings in Impax Laboratories by 112.7% during the 4th quarter. Commerce Bank now owns 24,375 shares of the specialty pharmaceutical company’s stock valued at $406,000 after acquiring an additional 12,915 shares during the period. OppenheimerFunds Inc. raised its holdings in Impax Laboratories by 15.6% during the 4th quarter. OppenheimerFunds Inc. now owns 29,480 shares of the specialty pharmaceutical company’s stock valued at $491,000 after acquiring an additional 3,977 shares during the period. TCW Group Inc. raised its holdings in Impax Laboratories by 3,904.5% during the 4th quarter. TCW Group Inc. now owns 1,987,950 shares of the specialty pharmaceutical company’s stock valued at $33,099,000 after acquiring an additional 1,938,307 shares during the period. Rhumbline Advisers raised its holdings in Impax Laboratories by 14.0% during the 4th quarter. Rhumbline Advisers now owns 177,081 shares of the specialty pharmaceutical company’s stock valued at $2,948,000 after acquiring an additional 21,775 shares during the period. Finally, Arizona State Retirement System raised its holdings in Impax Laboratories by 222.9% during the 4th quarter. Arizona State Retirement System now owns 124,564 shares of the specialty pharmaceutical company’s stock valued at $2,074,000 after acquiring an additional 85,988 shares during the period. 91.46% of the stock is currently owned by institutional investors and hedge funds.
Impax Laboratories (IPXL) opened at $19.45 on Tuesday. Impax Laboratories has a 1 year low of $7.75 and a 1 year high of $25.70. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.32 and a current ratio of 1.81. The company has a market cap of $1,447.07, a P/E ratio of -3.11, a price-to-earnings-growth ratio of 0.97 and a beta of 1.11.
ILLEGAL ACTIVITY WARNING: This piece was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://ledgergazette.com/2018/02/20/impax-laboratories-inc-ipxl-given-average-recommendation-of-hold-by-analysts.html.
Impax Laboratories Company Profile
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.